JAZZ Jazz Pharmaceuticals plc

Price (delayed)

$108.44

Market cap

$6.84B

P/E Ratio

20.73

Dividend/share

N/A

EPS

$5.23

Enterprise value

$11.16B

Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration ...

Highlights
Jazz Pharmaceuticals's equity has increased by 11% YoY
The gross profit has grown by 8% YoY
Jazz Pharmaceuticals's quick ratio has decreased by 18% YoY but it has increased by 7% from the previous quarter
Jazz Pharmaceuticals's net income has decreased by 20% QoQ
The company's EPS fell by 20% QoQ

Key stats

What are the main financial stats of JAZZ
Market
Shares outstanding
63.04M
Market cap
$6.84B
Enterprise value
$11.16B
Valuations
Price to book (P/B)
1.83
Price to sales (P/S)
1.76
EV/EBIT
21.49
EV/EBITDA
9.59
EV/Sales
2.9
Earnings
Revenue
$3.84B
EBIT
$519.28M
EBITDA
$1.16B
Free cash flow
$1.01B
Per share
EPS
$5.23
Free cash flow per share
$16.17
Book value per share
$59.29
Revenue per share
$61.46
TBVPS
$69.59
Balance sheet
Total assets
$11.33B
Total liabilities
$7.63B
Debt
$5.77B
Equity
$3.7B
Working capital
$1.98B
Liquidity
Debt to equity
1.56
Current ratio
2.27
Quick ratio
1.62
Net debt/EBITDA
3.71
Margins
EBITDA margin
30.3%
Gross margin
89.5%
Net margin
8.6%
Operating margin
13.5%
Efficiency
Return on assets
2.9%
Return on equity
9.2%
Return on invested capital
7.3%
Return on capital employed
5.3%
Return on sales
13.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

JAZZ stock price

How has the Jazz Pharmaceuticals stock price performed over time
Intraday
-1.15%
1 week
2.22%
1 month
0.44%
1 year
-17.16%
YTD
-11.84%
QTD
1.6%

Financial performance

How have Jazz Pharmaceuticals's revenue and profit performed over time
Revenue
$3.84B
Gross profit
$3.44B
Operating income
$518.73M
Net income
$330.79M
Gross margin
89.5%
Net margin
8.6%
The company's net margin fell by 20% QoQ
Jazz Pharmaceuticals's net income has decreased by 20% QoQ
JAZZ's operating margin is down by 11% since the previous quarter
The operating income has declined by 10% since the previous quarter

Growth

What is Jazz Pharmaceuticals's growth rate over time

Valuation

What is Jazz Pharmaceuticals stock price valuation
P/E
20.73
P/B
1.83
P/S
1.76
EV/EBIT
21.49
EV/EBITDA
9.59
EV/Sales
2.9
The company's EPS fell by 20% QoQ
The price to book (P/B) is 24% lower than the 5-year quarterly average of 2.4 and 17% lower than the last 4 quarters average of 2.2
Jazz Pharmaceuticals's equity has increased by 11% YoY
The price to sales (P/S) is 39% less than the 5-year quarterly average of 2.9 and 16% less than the last 4 quarters average of 2.1
The revenue has grown by 2.8% YoY

Efficiency

How efficient is Jazz Pharmaceuticals business performance
The company's return on assets fell by 22% QoQ
The return on equity has declined by 22% since the previous quarter
The company's return on sales fell by 11% QoQ
JAZZ's ROIC is down by 11% QoQ

Dividends

What is JAZZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for JAZZ.

Financial health

How did Jazz Pharmaceuticals financials performed over time
The total assets is 48% greater than the total liabilities
The company's current ratio fell by 26% YoY
Jazz Pharmaceuticals's quick ratio has decreased by 18% YoY but it has increased by 7% from the previous quarter
The company's debt is 56% higher than its equity
Jazz Pharmaceuticals's equity has increased by 11% YoY
Jazz Pharmaceuticals's debt to equity has decreased by 10% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.